



March 27, 2020

Michelle S. McOmber, MBA, CAE
Chief Executive Officer

Elected Officers
Matthew S. Wilson, MD
President

Dear Utah Physicians,

This is a time of great concern and unknowns for the health and well-being of our patients. As you are all aware, we do not know how drastically the COVID-19/Coronavirus pandemic will affect our patients, our healthcare system, our state, our country and the world. We have been working with the state and other entities to best see how we can serve the patients and physicians in Utah. We are sending out this information as a suggestion from the Utah Department of Health (UDOH). They are recommending that providers use a long-standing medication to treat COVID-19. This medication, Hydroxychloroquine, Hydroxychloroquine/zinc compound or Chloroquine/zinc is showing some promising data for affecting the course of COVID-19. While the data are limited and no double-blinded studies have been finished, we have attached some articles of studies that have been done and the findings.

Sharon R.M. Richens, MD
President-Elect
Howard R. Weeks, MD
Past President
Paul N. Clayton, MD
Speaker of the House
Mark R. Greenwood, MD
Vice Speaker of the House
Carissa S. Monroy, MD
At-Large Director
Jason R. Hoagland, MD
At-Large Director


The DOH is suggesting any of the following dosing for patients WHO TEST POSITIVE for COVID-19:

Hydroxychloroquine	Hydroxychloroquine/zinc	Chloroquine/zinc
200 mg Capsules	400/50 mg Capsules	500/50 mg Capsules
Take 1 BID x 5 days	Take 1 QD x 5 days	Take 1 QD x 7 days
Disp. #10 No refills authorized	Disp. #5 No refills authorized	Disp. #7 No refills authorized

This medication is an FDA approved medication that is used for other diseases. The UDOH does not suggest it be used for prophylaxis and the suggested dosing regimen is for a short period of time with no refills. For more details go to [Coronavirus.utah.gov](https://www.coronavirus.utah.gov) and click on the providers tab, when it is set up. If you have questions, contact UDOH. The Department has also asked that you track any improvements or changes in your patient's health after prescribing. At some point, they will ask for these data to be shared if you have tracked to see if it is making a difference. Utah is trying to study outcomes. The state has arranged for production of compounded medication, so we do not anticipate this will cause a shortage for patients who need it for other conditions.

As a reminder, UDOH is now recommending that ALL patients who have symptoms of Coronavirus get tested.

Thank you,


Matthew S. Wilson, MD
UMA President